Literature DB >> 708006

Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis.

S J Berman, W H Boughton, J G Sugihara, E G Wong, M M Sato, A W Siemsen.   

Abstract

A single 1.0-g dose of cefaclor administered to patients with stable end stage renal disease whose creatinine clearances were <5 ml/min produced a mean peak serum concentration of 48.3 +/- 19.8 mug/ml. The half-life was 2.3 +/- 0.3 h. Hemodialysis shortened the half-life of a similar dose to 1.6 +/- 0.3 h. Approximately one-third (340 mg) of the administered drug was recovered in the dialysate. Multiple doses of 500 mg every 6 h between hemodialysis sessions produced effective serum concentrations and no bioassay evidence of drug accumulation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 708006      PMCID: PMC352452          DOI: 10.1128/AAC.14.3.281

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  In vitro activity of cefaclor, a new orally administered cephalosporin antibiotic.

Authors:  J Santoro; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1977-09       Impact factor: 5.191

2.  Stability and blood level determinations of cefaclor, a new oral cephalosporin antibiotic.

Authors:  M A Foglesong; J W Lamb; J V Dietz
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

3.  Comparison of in vitro activity of cephalexin, cephradine, and cefaclor.

Authors:  N J Bill; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1977-03       Impact factor: 5.191

4.  Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients.

Authors:  C M Kunin; Z Finkelberg
Journal:  Ann Intern Med       Date:  1970-03       Impact factor: 25.391

5.  Cephalexin therapy as related to renal function.

Authors:  S A Kabins; B Kelner; E Walton; E Goldstein
Journal:  Am J Med Sci       Date:  1970-02       Impact factor: 2.378

6.  Cephalexin in patients with renal disease.

Authors:  J A Linquist; J Y Siddiqui; I M Smith
Journal:  N Engl J Med       Date:  1970-10-01       Impact factor: 91.245

7.  In vitro studies with cefaclor, a new oral cephalosporin.

Authors:  C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1977-10       Impact factor: 5.191

8.  Cephalexin: absorption and excretion as related to renal function and hemodialysis.

Authors:  B E Reisberg; J M Mandelbaum
Journal:  Infect Immun       Date:  1971-04       Impact factor: 3.441

  8 in total
  6 in total

1.  Cefaclor pharmacokinetic parameters: serum concentrations determined by a new high-performance liquid chromatographic technique.

Authors:  J C Rotschafer; K B Crossley; T S Lesar; D Zaske; K Miller
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

2.  Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis.

Authors:  J R Hess; S J Berman; W H Boughton; J G Sugihara; J E Musgrave; E G Wong; A M Siemsen
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 4.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

5.  Elimination of cefroxadine (CGP-9000) from patients undergoing dialysis.

Authors:  M J Nieto; J M Lanao; A Dominguez-Gil; J M Tabernero; J F Macias
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients.

Authors:  A Hishida; K Ohishi; S Nagashima; M Kanamaru; M Obara; A Kitada
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.